Table 1.
Clinicopathological features of prostate cancer patients with low PSA levels and high Gleason scores.
| Clinical characteristics | Unweighted, n (%) | P-value | ||||
|---|---|---|---|---|---|---|
| RP (n = 4,175) | EBRT (n = 4,114) | EBRT+BT (n = 825) | EBRT vs. RP | EBRT+BT vs. RP | EBRT+BT vs. EBRT | |
| Age at diagnosis | <0.001 | <0.001 | <0.001 | |||
| Mean (median) | 63.7 (64.0) | 70.6 (71.0) | 67.3 (68.0) | |||
| [range], year | [59.0–68.0] | [66.0–76.0] | [62.0–73.0] | |||
| PSA level | <0.001 | <0.001 | >0.999 | |||
| Mean (median) | 5.9 (5.7) | 6.3 (6.3) | 6.3 (6.1) | |||
| [range], ng/mL | [4.6–7.2] | [4.8–7.9] | [4.9–7.8] | |||
| Marital status | <0.001 | <0.001 | 0.228 | |||
| Married | 3,176 (76.1) | 2,747 (66.8) | 577 (70.0) | |||
| Divorced/widowed | 405 (9.8) | 623 (15.1) | 99 (12.0) | |||
| Singled | 376 (9.0) | 333 (8.1) | 74 (9.0) | |||
| Unknown | 218 (5.2) | 411 (10.0) | 75 (9.1) | |||
| Race | <0.001 | <0.001 | 0.001 | |||
| White | 3,298 (79.0) | 3,189 (77.5) | 595 (72.1) | |||
| Black | 524 (12.6) | 600 (14.6) | 161 (19.5) | |||
| Other | 309 (7.4) | 233 (5.7) | 58 (7.0) | |||
| Unknown | 44 (1.1) | 92 (2.2) | 11 (1.3) | |||
| AJCC T stage | <0.001 | <0.001 | 0.012 | |||
| T1 | 19 (0.5) | 2,241 (54.5) | 500 (60.6) | |||
| T2 | 2,608 (62.5) | 1,612 (39.2) | 278 (33.7) | |||
| T3 | 1,448 (34.7) | 228 (5.5) | 45 (5.5) | |||
| T4 | 100 (2.4) | 33 (0.8) | 2 (0.2) | |||
| Gleason score | <0.001 | >0.99 | 0.003 | |||
| 8 | 2,998 (71.8) | 2,601 (63.2) | 573 (69.5) | |||
| 9 | 1,116 (26.7) | 1,380 (33.5) | 238 (28.8) | |||
| 10 | 61 (1.5) | 133 (3.2) | 14 (1.7) | |||
RP, radical prostatectomy; EBRT, external beam radiotherapy; EBRT+BT, external beam radiotherapy with brachytherapy boost; PSA, prostate-specific antigen.